CCMI
ALNY icon

Creative Capital Management Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Creative Capital Management Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2K Buy
+4
New +$1.21K ﹤0.01% 1034

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Creative Capital Management Investments's ALNY Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 4 shares worth $1.2K. The stake represents ﹤0.01% of the portfolio and ranks #1034 among its holdings.

149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Creative Capital Management Investments held 4 shares of Alnylam Pharmaceuticals worth $1.2K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Creative Capital Management Investments position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1034 holding.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.